Drug Target Review2024-07-23T12:00:08
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-08-05T13:42:00
Sponsored by ICON plc., Drug Target Review
2026-09-18T15:56:00
Contributor Dr Garegin Papoian, Drug Target Review
2025-11-19T16:00:00
Sponsored by Eurofins DiscoverX
2023-07-04T10:05:58
Sponsored by Revvity
2023-11-20T13:43:43
Sponsored by Merck
2024-01-10T08:56:17
Sponsored by Leica Microsystems
Site powered by Webvision Cloud